CEBP  Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ireson, C. R.
Right arrow Articles by Gescher, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ireson, C. R.
Right arrow Articles by Gescher, A. J.
Cancer Epidemiology Biomarkers & Prevention Vol. 11, 105-111, January 2002
© 2002 American Association for Cancer Research

Metabolism of the Cancer Chemopreventive Agent Curcumin in Human and Rat Intestine

Christopher R. Ireson, Donald J. L. Jones, Samantha Orr, Michael W. H. Coughtrie, David J. Boocock, Marion L. Williams, Peter B. Farmer, William P. Steward and Andreas J. Gescher1

Medical Research Council Toxicology Unit, University of Leicester, Leicester LE1 9HN, United Kingdom [C. R. I., D. J. L. J., D. J. B., P. B. F., A. J. G.]; Human Tissue Bank and School of Pharmacy and Pharmaceutical Sciences, De Montfort University, Leicester LE1 9BH, United Kingdom [S. O.]; Department of Molecular and Cellular Pathology, University of Dundee, Ninewells Hospital & Medical School, Dundee DD1 9SY, United Kingdom [M. W. H. C.]; and Department of Oncology, University of Leicester, Leicester LE1 5WW, United Kingdom [M. L. W., W. P. S.]

Curcumin, the yellow pigment in turmeric, prevents malignancies in the intestinal tract of rodents. It is under clinical evaluation as a potential colon cancer chemopreventive agent. The systemic bioavailability of curcumin is low, perhaps attributable, at least in part, to metabolism. Indirect evidence suggests that curcumin is metabolized in the intestinal tract. To investigate this notion further, we explored curcumin metabolism in subcellular fractions of human and rat intestinal tissue, compared it with metabolism in the corresponding hepatic fractions, and studied curcumin metabolism in situ in intact rat intestinal sacs. Analysis by high-performance liquid chromatography, with detection at 420 or 280 nm, permitted characterization of curcumin conjugates and reduction products. Chromatographic inferences were corroborated by mass spectrometry. Curcumin glucuronide was identified in intestinal and hepatic microsomes, and curcumin sulfate, tetrahydrocurcumin, and hexahydrocurcumin were found as curcumin metabolites in intestinal and hepatic cytosol from humans and rats. The extent of curcumin conjugation was much greater in intestinal fractions from humans than in those from rats, whereas curcumin conjugation was less extensive in hepatic fractions from humans than in those from rats. The curcumin-reducing ability of cytosol from human intestinal and liver tissue exceeded that observed with the corresponding rat tissue by factors of 18 and 5, respectively. Curcumin sulfate was identified in incubations of curcumin with intact rat gut sacs. Curcumin was sulfated by human phenol sulfotransferase isoenzymes SULT1A1 and SULT1A3. Equine alcohol dehydrogenase catalyzed the reduction of curcumin to hexahydrocurcumin. The results show that curcumin undergoes extensive metabolic conjugation and reduction in the gastrointestinal tract and that there is more metabolism in human than in rat intestinal tissue. The pharmacological implications of the intestinal metabolism of curcumin should be taken into account in the design of future chemoprevention trials of this dietary constituent.




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
Y. Zeng, F. Qiu, Y. Liu, G. Qu, and X. Yao
Isolation and Identification of Phase 1 Metabolites of Demethoxycurcumin in Rats
Drug Metab. Dispos., September 1, 2007; 35(9): 1564 - 1573.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
W. Zhang, T. M. C. Tan, and L.-Y. Lim
Impact of Curcumin-Induced Changes in P-Glycoprotein and CYP3A Expression on the Pharmacokinetics of Peroral Celiprolol and Midazolam in Rats
Drug Metab. Dispos., January 1, 2007; 35(1): 110 - 115.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
T. Sicilia, A. Bub, G. Rechkemmer, K. Kraemer, P. P. Hoppe, and S. E. Kulling
Novel Lycopene Metabolites Are Detectable in Plasma of Preruminant Calves after Lycopene Supplementation
J. Nutr., November 1, 2005; 135(11): 2616 - 2621.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Fang, J. Lu, and A. Holmgren
Thioredoxin Reductase Is Irreversibly Modified by Curcumin: A NOVEL MOLECULAR MECHANISM FOR ITS ANTICANCER ACTIVITY
J. Biol. Chem., July 1, 2005; 280(26): 25284 - 25290.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
Y. Song, N. D. Sonawane, D. Salinas, L. Qian, N. Pedemonte, L. J. V. Galietta, and A. S. Verkman
Evidence against the Rescue of Defective {Delta}F508-CFTR Cellular Processing by Curcumin in Cell Culture and Mouse Models
J. Biol. Chem., September 24, 2004; 279(39): 40629 - 40633.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
S. Nowell, D. L. Ratnasinghe, C. B. Ambrosone, S. Williams, T. Teague-Ross, L. Trimble, G. Runnels, A. Carrol, B. Green, A. Stone, et al.
Association of SULT1A1 Phenotype and Genotype with Prostate Cancer Risk in African-Americans and Caucasians
Cancer Epidemiol. Biomarkers Prev., February 1, 2004; 13(2): 270 - 276.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
Curcumin Derivatives: Potential for Prostate Cancer Management: ADDANKI P. KUMAR, GRETCHEN E. GARCIA, RITA GHOSH, RAJENDRAN V. RAJNARAYANAN,1 WILLIAM L. ALWORTH,1 AND THOMAS J. SLAGA, Center for Cancer Causation and Prevention, AMC Cancer Research Center and University of Colorado Comprehensive Cancer Center, Denver, Colorado 80214; 1 Department of Chemistry, Tulane University, New Orleans, Louisiana 70118
Toxicol Pathol, January 1, 2004; 32(1): 161 - 163.
[PDF]


Home page
Drug Metab. Dispos.Home page
H.-L. Fang, S. Shenoy, Z. Duanmu, T. A. Kocarek, and M. Runge-Morris
TRANSACTIVATION OF GLUCOCORTICOID-INDUCIBLE RAT ARYL SULFOTRANSFERASE (SULT1A1) GENE TRANSCRIPTION
Drug Metab. Dispos., November 1, 2003; 31(11): 1378 - 1381.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2002 by the American Association for Cancer Research.